Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform [View article]
Nice article, I like these stocks too. Another one that appears to have major upside from just 63 cents is Palatin (PTN) they have an obesity candidate and a partnership deal with AstraZeneca (AZN) plus a FSD candidate w positive phase 2. Roth Capital has a $6 price target so that implies huge upside from current levels. Here is the link:
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Engbulldog, PTN is trading for just a bit less than cash value so if it gets positive results, chances are it will surge before you can buy it this cheap. Hard to find a biotech trading for less than cash that also has a $145 million agreement with a major biopharma co, and that also has obesity drug potential and positive data on FSD. I think that is why Roth Capital sees it as being so undervalued right now as they have a $6 price target.
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Reasonable Risk, According to the balance sheet data last reported to Capital IQ on Yahoo Finance, the debt levels mentioned above (in the article) are correct as of the last quarter reported by ARNA and VVUS. Take a look for yourself and you can see it shows that ARNA has debt:
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Smit3413, here is some more info:
PTN has about $33 million in cash on the balance sheet, and and almost no debt ($31,000). Plus it has the $145 million agreement with AZN and the book value is 81 cents per share which is made up of cash. The FSD data has been positive and so the obesity drug development would just be a real bonus. I like that PTN stock has built a nice bottom/base around current levels and with such a strong balance sheet and the AZN agreement, seems to have limited downside with major upside as indicated by Roth Capital's $6 price target.
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Yes, PTN is still developing an obesity drug treatment with AstraZeneca which as the quote from Roth Capital states above is still committed to the obesity program even though they had a setback with one version last year. Obviously the FSD potential for PTN is looking good now and that is also probably a big reason why the Roth Capital analysts think PTN is worth $6 per share as development continues, but with AstraZeneca still committed to paying up to $145 million to PTN, the obesity drug potential for PTN is also huge from these levels. The other big plus is that PTN already has a cash rich balance sheet and money coming in from AstraZeneca to continue funding the obesity candidate.
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Artlvr, Vivus is in the process of commercializing Stendra with/to partners now which is essentially a form of being on the market even if they are not shipping product yet in U.S., thanks for clarifying this point. Plus the link to co website below states " In South Korea, STENDRA is approved and is marketed by JW Pharma under the brand name Zepeed."
As for point 2) yes it is the same but for different indications.
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Plus, with Palatin (PTN) at just 64 cents, and with the Roth Capital partners price target at $6, PTN probably has the most upside of any stock here. But some of the other look good too!
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
Frank, thanks for the comments. I agree the potential updisde for PTN could be huge since it is a real sleeper stock that has the backing (agreement) with AZN. Positive data on FSD is very encouraging!
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013 [View article]
Thank you. Yes, it looks like the upgrade that was released this morning caused the stock to move today. I agree with you, technically it could go to 90 cents plus soon.
These 4 Cheap Commodity Stocks Could Be Poised For A Strong Rebound [View article]
Thanks for your posts Tommiegun, I agree Metalico (MEA) looks way to cheap and I plan on buying it! I think it has the best short term and long term potential here.
Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperform [View article]
http://bit.ly/184KaYO
This Summer Slowdown Will Be Different Than The Previous 3 [View article]
Lot78 Inc: Why This $240 Million Company Could Drop By 75% Or More [View article]
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
http://yhoo.it/14chttx
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
PTN has about $33 million in cash on the balance sheet, and and almost no debt ($31,000). Plus it has the $145 million agreement with AZN and the book value is 81 cents per share which is made up of cash. The FSD data has been positive and so the obesity drug development would just be a real bonus. I like that PTN stock has built a nice bottom/base around current levels and with such a strong balance sheet and the AZN agreement, seems to have limited downside with major upside as indicated by Roth Capital's $6 price target.
balance sheet info:
http://yhoo.it/YSy1PZ
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
As for point 2) yes it is the same but for different indications.
http://bit.ly/17XDJab
Hope it does well for you!
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
These Obesity Stock Plays Could Offer 'Blockbuster' Drug Potential [View article]
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013 [View article]
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013 [View article]
These 4 'High-Potential' Biotech Stocks Could Outperform In 2013 [View article]
These 4 Cheap Commodity Stocks Could Be Poised For A Strong Rebound [View article]
Why These Below $6 Tech Stocks Are Now Too Cheap To Ignore [View article]